This study examined Barrett ' s esophagus (BE) risk factors in veterans to determine the association between risk of BE and use of oral bisphosphonates.
INTRODUCTION
Bisphosphonates are selective inhibitors of osteoclastmediated bone resorption that are used for the treatment and prevention of osteoporosis. The use of oral bisphosphonates has increased dramatically in recent years, despite its association with adverse gastrointestinal effects, including an increased risk of esophagitis, esophageal erosions, and esophageal ulcers ( 1,2 ).
Barrett ' s esophagus (BE) is a known premalignant precursor lesion in most cases of esophageal adenocarcinoma and is a relatively common problem, thought to aff ect 1 -2 % of the general population ( 3, 4 ) . Th e risk of esophageal adenocarcinoma in patients with BE is 30 -125 times greater than the general population ( 5 ) . Th e US Food and Drug Administration (FDA) reported on several cases of esophageal adenocarcinoma in bisphosphonate users ( 6, 7 ) . Some of these patients also carried a diagnosis of BE. Th e author of that FDA report cautioned physicians to avoid prescribing oral bisphosphonates to patients with BE ( 7 ) . However, recent population-based studies examining the association between bisphosphonate use and esophageal adenocarcinoma have arrived at confl icting results ( 8 -11 ) . Moreover, to assess the safety of oral bisphosphonates, it is important to examine its association with BE. To our knowledge, there are no published studies on this subject.
Oral Bisphosphonates and the Risk of Barrett ' s Esophagus: Case -Control Analysis of US Veterans
We conducted a case -control study to examine BE risk factors in a large population of US veterans. Here we report the association between the risk of BE with oral bisphosphonate use, ascertained by pharmacy records.
METHODS

Study population
We used data from a case -control study of BE risk factors conducted at the Michael E. DeBakey Veterans Aff airs Medical Center (MEDVAMC) in Houston, Texas. Details of this study population have been previously described ( 12 ) . Briefl y, participants were recruited at MEDVAMC either before an elective esophagogastroduodenoscopy (EGD) for any indication from 1 September 2008 to 20 March 2012 or from among patients eligible for screening colonoscopy who attended one of seven selected MEDVAMC primary care clinics from 1 September 2008 to 31 December 2010. No primary care patients were primarily referred for EGD; if they agreed to participate in the study, they underwent the study EGD at the same time as their colonoscopy. Th e minimum age limit for the EGD group (40 years) was lower than that for the primary care group (50 years). Patients with a previous history of gastroesophageal surgery or diagnosis of cancer, currently taking anticoagulants, with signifi cant liver disease (as indicated by platelet count < 70,000, ascites, or known gastroesophageal varices), or with a history of major stroke or mental disorder were ineligible for the study.
Cases were patients with both endoscopically suspected and histologically confi rmed BE (i.e., specialized intestinal metaplasia on targeted biopsy from suspected BE areas). We excluded patients with only endoscopically suspected BE from the analysis; however, if they had histologically confi rmed BE on a follow-up EGD they were included as BE cases. We compared the BE cases with two control groups: participants without endoscopically suspected BE who underwent an elective EGD ( " endoscopy controls " ) and those recruited from primary care without endoscopically suspected BE on their study EGD ( " primary care controls " ). Waist and hip circumferences were measured, and waist-to-hip ratios were calculated. Height in inches was also obtained, and body mass index was calculated using the Quetlet index formula.
All participants completed a computer-assisted survey with guidance from a trained research assistant. Th e survey elicited information about race and ethnicity, social background, frequency and severity of gastroesophageal refl ux disorder (GERD) symptoms, cigarette smoking, alcohol use, medical history, ever use of protonpump inhibitors (PPIs), and use of aspirin and nonsteroidal antiinfl ammatory drugs (NSAIDs) in the past year.
For this study, information on oral bisphosphonate use was primarily obtained through manual searches of the Computerized Patient Record System, the VA electronic medical record system, for all fi lled (dispensed) prescriptions of the following oral bisphosphonates: alendronate (Fosamax), etidronate (Didronel), ibandronate (Boniva), pamidronate (Aredia), risedronate (Actonel, Atelvia), and tiludronate (Skelid). Th ese prescriptions could have been either mailed or picked up at the window pharmacy.
Th e self-reported survey also included questions about bisphosphonate use.
Statistical analysis
Bisphosphonate use was defi ned based on the fi ndings of chart reviews of VA pharmacy data. We calculated the proportions of cases and controls with dispensed bisphosphonate prescriptions. We fi tted logistic regression models to calculate odds ratios (ORs) and 95 % confi dence intervals (95 % CIs) for the association between oral bisphosphonates and the risk of BE, using combined control groups and each control group separately. In multivariate analyses, we adjusted for age, sex, race (White, Other), smoking status (nonsmoker, ex-smoker, current smoker), GERD symptoms (never, < 10 years, 10 + years), PPI use (never, ever), H. pylori infection (positive, negative), waist-to-hip ratio (high and low risk), and hiatal hernia (None, < 3 cm, ≥ 3 cm). Stratifi ed analyses were performed, based on the presence of GERD symptoms, PPI use or both, or NSAID use. Statistical analyses were performed using SAS 9.2 (SAS Institute, Cary, NC). Statistical signifi cance was determined at α = 0.05, and all tests for statistical signifi cance were two sided.
RESULTS
Among the 2,226 eligible patients who arrived at their elective EGD appointment and were contacted by our study staff , 1,912 met the study criteria, and 1,489 were enrolled in the study. Among 1,309 eligible primary care patients who were invited to participate, 603 were enrolled in the study. We subsequently excluded 22 patients who withdrew consent, 48 patients without a complete study EGD, and 119 patients with BE only endoscopically suspected but not confi rmed (i.e., specialized intestinal metaplasia was absent on biopsy). Of the patients who were screened and found eligible on or before 20 March 2012, a greater percentage of women (33.8 % vs. 28.1 % , P = 0.009), whites (30.4 vs. 26.9 % (black) vs. 14.4 % (other), P < 0.001), and endoscopy patients (34.5 % vs. 19.6 % (primary care), P < 0.001) were enrolled than their counterparts.
We, therefore, had 1,903 patients analyzed in this study: 285 cases of denitive BE, 1,122 endoscopy controls, and 496 primary care controls. Th e mean age of the study cohort was 60.5 years (s.d. 7.9), and 92.3 % were men. Most were white (64.5 % ) or black (32.5 % ). Comparisons of demographic, anthropometric, and specifi c clinical characteristics of the BE cases and the combined control groups are shown in Table 1 . Patients with defi nite BE were more likely to be male (97.2 % vs. 91.5 % , P < 0.001) and white (86.3 % vs. 61.1 % , P < 0.001) and an average 1.2 years older than controls ( P = 0.009). Th e presence of GERD symptoms (61.6 % vs. 46.0 % , P < 0.001), as well as a long history of GERD symptoms (11.6 vs. 7.4 years, P < 0.001), was signifi cantly more common in BE cases than in the combined control groups. PPI use was signifi cantly more common in BE cases (70.4 % vs. 51.6 % , P < 0.001). Th ere was no signifi cant diff erence in self-reported NSAID use in the past year between BE cases and combined control groups (47.4 % vs. 50.0 % , P = 0.45).
Filled prescriptions for oral bisphosphonates before study endoscopy were ascertained in 54 (2.8 % ) study participants in a ESOPHAGUS Lin et al. systematic review of electronic pharmacy records for all participants. Only 6 of these 54 patients reported taking alendronate on the self-reported survey. On the other hand, no study participants who did not have oral bisphosphonate prescriptions in their medical records self-reported bisphosphonate use. Th e only two oral bisphosphonates prescribed in this study were alendronate ( n = 48) and risedronate ( n = 6). Oral bisphosphonates were signifi cantly more commonly prescribed for older, white, and female participants than for their counterparts ( Table 2 ) . Greater proportions of patients on bisphosphonates were also prescribed PPIs and had GERD symptoms than those not on bisphosphonates, although the diff erences in GERD symptoms were not statistically significant ( Table 2 ) . A greater proportion of BE cases had fi lled prescriptions for any oral bisphosphonate than the combined groups of controls (4.6 % vs. 2.5 % ; P = 0.078), and signifi cantly greater proportions of BE cases had alendronate than controls (4.2 % vs. 2.2 % , P = 0.045). To examine if increased healthcare contacts may make patients more likely to receive a bisphosphonate prescription, we excluded the 68 prevalent BE cases from the analysis and only included newly diagnosed BE cases. Th ere was an even higher proportion of BE cases with any fi lled oral bisphosphonate or alendronate prescriptions (4.9 % vs. 4.4 % , respectively) than those in the combined controls (2.5 % vs. 2.2 % , respectively). Th e P -value for the χ 2 test for any bisphosphonate increased from 0.078 to 0.041, and that for oral alendronate use changed only slightly from 0.045 to 0.040.
Th ere were no signifi cant diff erences in the duration of prescriptions between cases and the combined controls (23.1 vs.
29.8 months, P = 0.45) or in the mean cumulative dose (3,473 mg (s.d. 4,164) vs. 5,691 mg (s.d. 6,013), P = 0.22). Th e proportions of patients with 5 mg and ≥ 10 mg weekly doses were slightly greater in cases than controls (2.1 % vs. 0.9 % and 2.5 % vs. 1.7 % , respectively; P = 0.106). Th is analysis was limited by the small numbers in the dose groups.
We also compared the distribution of bisphosphonate prescriptions between cases and each control group separately and found signifi cantly higher usage in cases than in primary care controls (1.6 % , P = 0.02), but not endoscopy controls (2.9 % , P = 0.19). Alendronate accounted for most of the oral bisphosphonate prescriptions in BE cases, primary care controls, and endoscopic controls, 31 (93.9 % ), 5 (62.5 % ), and 12 (92.3 % ), whereas risedronate accounted for only 2, 3, and 1 patients in the three groups, respectively.
In the multiple regression model, oral bisphosphonates were signifi cantly associated with a greater than twofold increased risk of BE (OR = 2.33; 95 % CI: 1.11 -4.88) compared with the combined control groups aft er adjustment for sex, age, race, PPI use, hiatal hernia, waist-to-hip ratio, H. pylori infection, and GERD symptoms ( Table 3 ). Removing the prevalent 68 BE cases from the analysis and examining only newly diagnosed BE cases slightly changed the OR from 2.33 to 2.45, with the P value being unchanged ( P = 0.025).
Th e risk of BE with bisphosphonate use was slightly higher when we examined BE cases compared with endoscopy control patients only (OR = 2.74; 95 % CI: 1.28 -5.87), but the association was of borderline signifi cance (OR = 2.60; 95 % CI: 0.99 -6.84) when with defi nitive BE, endoscopic only BE cases were signifi cantly more likely to take bisphosphonate (6.7 % vs. 2.2 % P = 0.003) than combined controls. Signifi cantly more bisphosphonate users had esophageal erosions (22.6 % vs. 11.0 % of nonusers, P = 0.005); most erosion were grade A (9.5 % ) followed by grade B (5.3 % ) and grade C (2.0 % ).
DISCUSSION
In this large, single-center, case -control study, mostly of male veterans, we found a signifi cant association between previous or current use of oral bisphosphonates and the presence of BE. Th e use of oral bisphosphonates was associated with a greater than twofold increase in risk of BE than in control patients aft er adjustment for sex, age, race, PPI use, hiatal hernia, waist-to-hip ratio, H. pylori infection, and GERD symptoms. Th e association between oral bisphosphonates and BE was seen only among patients with frequent GERD symptoms, PPI use, or both. BE is thought to develop from an infl ammatory process caused by chronic gastroesophageal refl ux contents leading to mucosal injury and DNA damage ( 13 ) . Mediators of infl ammation such as nuclear factor-κ B have been linked to the induction of CDX genes that play an important role in the initiation of BE (14, 15) . Similarly, evidence suggests that bisphosphonate users develop esophagitis, esophageal erosions, and esophageal ulcers through direct topical injury, as esophageal biopsies have revealed foreign material consistent with the appearance of alendronate tablets ( 16 ) . It is plausible that, through a common infl ammatory process, oral bisphosphonates could be associated with BE.
Th e mechanisms underlying the association between BE and bisphosphonates are unknown. Th e nitrogen-containing bisphosphonates including alendronate and risedronate, which were used by subjects in this study, act by inhibiting the mevalonate pathway through farnesyl diphosphate synthase ( 17 ) . Th e in vitro models of human epidermal keratinocytes exposed to alendronate or risedronate revealed suppression of epithelial cell growth via inhibition of farnesyl diphosphate synthase in the mevalonate to cholesterol pathway; the resulting reduction in cholesterol synthesis and geranylgeranylation suppresses cell growth by interfering with progression through the cell cycle ( 18 ) . Th e inhibition of esophageal epithelial stem cells could potentiate the damage of gastroesophageal refl ux and lead to inactivation of squamous diff erentiation and activation of columnar diff erentiation.
We observed that the association between bisphosphonate use and BE was modifi ed by the presence of GERD symptoms, PPI use, and NSAID use. Th ese factors could facilitate or inhibit the way oral bisphosphonates aff ect BE development. For example, there could be a potentiating eff ect for GERD, which is the most common risk factor for BE. PPIs are the primary antisecretory treatment for patients with GERD-related syndromes ( 19 ) , and therefore they could a marker of GERD. NSAIDs have been studied in observational studies for a potentially protective eff ect against BE ( 20, 21 ) .
Bisphosphonates have come under the scrutiny of the FDA Advisory Committee for Reproductive Health Drugs and Drug Safety we compared BE cases with primary care control patients only. However, this analysis was limited by a small number of bisphosphonate users in the primary care control group ( n = 8).
We examined the association between bisphosphonates and BE in several stratifi ed analyses ( Table 3 ) . Th e association between oral bisphosphonates and BE increased when limited to patients with GERD symptoms (OR = 3.29; 95 % CI: 1.36 -7.97). However, no association was observed in patients without GERD symptoms (OR = 0.86; 95 % CI: 0.19 -3.93). A similar relationship was also present when examining PPI use; we observed an association between oral bisphosphonates and BE among those using PPIs (OR = 2.71; 95 % CI: 1.15 -6.41) but no signifi cant association in patients without PPI use (OR = 1.56; 95 % CI: 0.32 -7.52). Finally, among NSAID users, there was no signifi cant association between bisphosphonates and BE (OR = 1.23; 95 % CI: 0.38 -3.95), whereas among participants with no reported NSAID use, the OR increased to 4.51 (95 % CI: 1.49 -13.65).
We also compared 119 patients endoscopic only (without specialized intestinal metaplasia) BE cases, and found no signifi cant diff erences from patients with defi nitive BE in fi lled bisphosphonate prescriptions (4.6 % vs. 6.7 % , P = 0.37). Similar to the fi ndings GERD, gastroesophageal refl ux disease; PPI, proton-pump inhibitor.
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and Risk Management Committee in response to post marketing reports of rare but serious adverse events, including esophageal cancer ( 22 ) . A total of 34 cases were submitted to the FDA Adverse Event Reporting System of esophageal cancer of unspecifi ed histological type in bisphosphonate users during 1998 -2009. Histological analysis showed adenocarcinoma in 7 patients and squamous cell carcinoma in 1 patient. An additional 34 cases of esophageal cancer among bisphosphonate users were also reported from Europe and Japan. Histological analysis showed adenocarcinoma in six patients and squamous cell carcinoma in fi ve patients. One patient from the United States and three patients from Europe and Japan concomitantly carried a diagnosis of BE ( 3 ). All cases reported in the United States and most cases in Europe and Japan involved alendronate as the suspect bisphosphonate. Th e bisphosphonate use in our study was predominantly alendronate (89 % ) rather than risedronate (11 % ). Animal models have shown that risedronate, a pyridinyl bisphosphonate, induces less gastric damage compared with the primary amino bisphosphonates including pamidronates ( 23, 24 ) . Subsequently, population-based studies conducted in the United Kingdom, Denmark, and Taiwan have arrived at confl icting results regarding the use of bisphosphonates and esophageal cancer ( 8 -11 ) . Green et al. ( 8 ) showed an increased risk between oral bisphosphonates and esophageal cancer, whereas the other three studies concluded that oral bisphosphonates were not likely risk factors for esophageal cancer. Only one study by Cardwell et al. ( 9 ) , conducted among 46,036 bisphosphonate users, reported on prior BE diagnosis, but rates of BE were low, accounting for 0.5 % of the study participants, with only 1 patient developing cancer.
It is unknown how bisphosphonate use infl uences adenocarcinoma risk in BE. A recent study conducted of a national VA cohort of patients with BE found that oral bisphosphonates were not associated with an increased risk of esophageal adenocarcinoma, but this study was limited by only 2 cases (of 116 total cases) being exposed to oral bisphosphonates ( 25 ) . Th is is further complicated by growing evidence that bisphosphonates demonstrate antitumor activity through inhibition of the mevalonate pathway that has been implicated in various aspects of tumor development and progression ( 26 -28 ) .
Th e strengths of our study include a large sample size and the accurate endoscopic and histologic defi nition of cases and controls. All patients completed a comprehensive survey before the EGD to capture several potential confounders. Oral bisphosphonate use was ascertained by fi lled prescriptions in the electronic pharmacy records and supplemented by self-report information in all cases and controls. Exposure to the medication was based on prescriptions that were actually fi lled. Finally, corroborating the known associations between BE and older age, male sex, white race, GERD symptoms, and waist-to-hip ratio confers internal validity to the new observation related to bisphosphonates. However, our study has several limitations. It was conducted at a single-center VA medical center, where patients are likely to be older men, which may limit the generalizability of the results. Patients who were enrolled in this study may have received bisphosphonates from non-VA pharmacies, although studies have shown that veterans who use the VA healthcare system tend to disproportionately or exclusively use VA pharmacy services ( 29 ) . Th ere are no data as to whether oral bisphosphonates were taken according to directions, which require patients to remain upright for at least 30 min aft er ingestion, or as to the actual ingestion of medications, given that compliance with oral bisphosphonates is already known to be suboptimal ( 30 ) . Of the 54 patients with a fi lled bisphosphonate prescription, only 6 reported taking alendronate on the self-reported survey. Th is could indicate a high percentage of noncompliance, although we believe that using the electronic pharmacy data for fi lled (dispensed) prescription is a more accurate and complete method for ascertaining medications use than self-report. Polypharmacy, which is quiet high among older veteran patients, likely contributed to the inaccuracy of self-report information in this study. Although we conducted a survey with an extensive questionnaire to document potential confounders, we cannot rule out other residual confounding from unmeasured or poorly measured variables. For example, the BE cases in this study were more likely than controls to have a long history of GERD symptoms. Oral bisphosphonate use may have worsened existing symptoms, leading to presentation to a physician and subsequent recruitment for a research endoscopy and the possible introduction of a selection bias.
In conclusion, among 285 veterans with denitive BE and 1,618 controls, we found a signifi cant association between oral bisphosphonate use and an increased risk of BE, especially among patients with GERD symptoms, those on PPI treatment, or those not taking NSAIDs. Th is is the fi rst published study on this association. Additional studies are needed to further examine this association, as it could suggest an increased risk of esophageal cancer in oral bisphosphonate users.
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